4 M$ investment agreement to prepare the clinical study of an improved chemotherapy

October 30th, 2024

Opening of the 2nd tranche of OpPacli™'s preclinical round

October 30th, 2024

First patents granted to Pharma in silica

January 29th, 2024

Pharma in silica receives positive feedback from FDA and Health Canada, paving the way for OpPacli™ clinical trials

November 20th, 2023

$ 2M toward an efficient and lenient chemotherapy: the government of Québec and 6 individual investors enter the capital of Pharma in silica

May 2nd, 2023

Ms. Isabelle Tremblay joins the board of directors of Pharma in silica

December 28th, 2022

Pharma in silica acquires the founding intellectual property on the OpKemo technology

July 29th, 20232

Pharma in silica launches its first preclinical program

June 1st 2022

Pharma in silica's scientific coordinator takes up her post

April 15th, 2022

Conclusion of the OptiSpheres 3 program

July 15th, 2021

Pharma in silica inaugurates its new high-safety laboratory

November 4th, 2020

The City of Québec financially supports Pharma in silica

February 3rd, 2020

Mr Bertrand Bolduc joins Pharma in silica inc.'s board of directors

November 18th, 2019

For a safe chemotherapy: Pharma in silica starts up

August 30th, 2019